---
layout: default
title: Tretinoin
parent: 僅模型預測 (L5)
nav_order: 1257
evidence_level: L5
indication_count: 10
---

# Tretinoin
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Tretinoin: From Unspecified Indication to Rheumatoid Nodulosis

## One-Sentence Summary

> The evidence pack does not document Tretinoin's original approved indication (no license or indication text is on file, and the drug is currently **not marketed** in this jurisdiction).
> The TxGNN model's top-ranked prediction for this drug is **Rheumatoid Nodulosis**,
> but currently **0 clinical trials** and **0 publications** support this specific prediction — it is a pure knowledge-graph score with no corroborating evidence.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not documented in the evidence pack (no licenses on file) |
| Predicted New Indication | Rheumatoid Nodulosis |
| TxGNN Prediction Score | 99.84% (rank #4836 in the model's candidate list) |
| Evidence Level | L5 — model prediction only, no clinical or literature support |
| Market Status | Not Marketed (未上市) |
| Number of Licenses | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack (flagged as a High-severity data gap), and no original indication information is on file for Tretinoin locally. Based on general pharmacology captured in the model's rationale, Tretinoin is a RAR/RXR (retinoic acid receptor) agonist with known immunomodulatory activity — including effects on the Th17/Treg balance — which theoretically could influence rheumatoid-associated inflammatory processes. However, this is a **mechanistic hypothesis only**; no direct clinical or preclinical study in the evidence pack tests Tretinoin specifically against rheumatoid nodulosis.

It is worth noting that among the 10 candidate indications returned for this drug, only two (Osteoarthritis, rank 7, and Quinquaud's Folliculitis Decalvans, rank 10) have any literature evidence at all, and both remain at evidence level L4 (mechanistic/preclinical, no clinical trials). The top-ranked candidate discussed here, Rheumatoid Nodulosis, has neither literature nor trial support — its score reflects graph connectivity in TxGNN's knowledge base rather than an evidenced therapeutic signal.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Safety Considerations

Please refer to the package insert for safety information. (Key warnings, contraindications, and drug-drug interaction data are all currently unavailable — TFDA labeling retrieval is flagged as a **blocking** data gap in this evidence pack.)

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
- The top-ranked predicted indication (Rheumatoid Nodulosis) is an L5-level, pure model prediction with zero supporting clinical trials or publications. A blocking data gap (missing TFDA labeling) also prevents any safety pre-screening (S1 gate), and MOA confirmation is still pending.

**To proceed, the following is needed:**
- TFDA package insert / warnings & contraindications (currently blocking — DG001)
- Confirmed mechanism of action via DrugBank query (DG002)
- Original indication and regulatory history for Tretinoin, to establish an indication-to-indication rationale
- Primary or preclinical evidence specific to rheumatoid nodulosis (none currently identified)
- Consider redirecting evaluation effort toward the two candidates with existing literature support — Osteoarthritis (rank 7, L4) and Folliculitis Decalvans (rank 10, L4) — as they are further along the evidence curve than the top-ranked prediction
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

